ArticleJournal of cellular and molecular medicine2026
Sesamin Ameliorates High-Sugar, High-Fat Diet-Induced Hepatic Dysfunction via CYP1A2-Mediated Regulation of Lipid Metabolism and Oxidative Stress.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BackgroundHigh-sugar, high-fat diets (HSDFD) can lead to hepatic dysfunction, but the molecular mechanisms underlying protective compounds like sesamin remain unclear MethodsWe employed a multi-faceted approach combining in silico and in vivo techniques. Utilizing the AlphaFold database, we screened multi-species proteomes to identify potential sesamin targets. Molecular dynamics simulations and MM-PBSA analysis were used to characterize sesamin-protein interactions. In vivo studies included single-cell RNA sequencing of hepatocytes from HSDFD-fed mice. We validated our findings using cellular thermal shift assays (CETSA), drug affinity responsive target stability (DARTS) assays, Western blotting, and qPCR. ResultsHSDFD induced significant redistribution of hepatocyte subpopulations with high CYP1A2 abundance. Computational analysis identified CYP1A2 as a direct target of sesamin, with species-specific interaction patterns. Sesamin exhibited stable binding to CYP1A2, modulating its activity through subtle conformational changes. Key residues F451 and I386 were crucial for sesamin's regulation of CYP1A2-mediated ROS production. Sesamin supplementation ameliorated HSDFD-induced hepatic dysfunction by modulating fatty acid metabolism and oxidative stress responses. ConclusionOur study unveils CYP1A2 as a key molecular target of sesamin in HSDFD-induced hepatic dysfunction, providing new insights into potential therapeutic strategies for metabolic liver disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.